# Focused Ultrasound and Pembrolizumab in Metastatic Breast Cancer

> **NCT03237572** · PHASE1 · TERMINATED · sponsor: **Patrick Dillon, MD** · enrollment: 13 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Pembrolizumab
- **DEVICE:** High-intensity focused ultrasound (HIFU)

## Key facts

- **NCT ID:** NCT03237572
- **Lead sponsor:** Patrick Dillon, MD
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-09-25
- **Primary completion:** 2022-06-01
- **Final completion:** 2022-06-17
- **Target enrollment:** 13 (ACTUAL)
- **Why stopped:** Low rate of enrollment
- **Last updated:** 2026-02-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03237572

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03237572, "Focused Ultrasound and Pembrolizumab in Metastatic Breast Cancer". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03237572. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*